FivepHusion has announced the appointment of Iain Ross to its board as a non-executive director.
Mr Ross is an experienced international biotechnology executive, currently serving as an executive chairman and in non-executive chairman roles for UK and US publicly listed and private companies. He lives in the UK and is a frequent visitor to Australia.
David Ranson, executive chairman of FivepHusion, said, “As we pursue late clinical-stage development of our lead drug Deflexifol, augmenting and expanding the diversity and skill set of our Board is paramount to optimally positioning our company for global development activities and commercialisation. I am thrilled that Iain has agreed to contribute his deep experience and global perspective to our company.”
Mr Ross added, “I am excited to join the FivepHusion Board at this important inflection in the development of Deflexifol™, which has the potential to help a very large number of cancer patients globally. Through the strategic global partnerships that FivepHusion has established, it is well placed to rapidly advance Deflexifol to significant development and commercial milestones. I look forward to working with the Board, and on behalf of the company’s investors, on this exciting journey.”